LUNG Pulmonx Corporation
USHealthcareAs of 2026-07-02
Why LUNG matters now
Pulmonx Corporation (LUNG) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.39 with -5.44% on the session and $58.7M in market capitalization; recent performance reads 1-month -4.48% and YTD -42.08%.
The latest financial table shown here is Q1 2026, with revenue of $20.6M, net income of $-13.7M, and EPS of $-0.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -54.5%.
The latest indexable market news headline is "Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from Globe News Wire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $9.75; recent insider activity includes Mead Dana G Jr. filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.17
P/S
0.61
EV/EBITDA
-1.01
DCF Value
$-9.37
FCF Yield
-54.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.5%
Operating Margin
-58.8%
Net Margin
-60.1%
ROE
-92.9%
ROA
-44.4%
ROIC
-50.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $20.6M | $-13.7M | $-0.33 |
| Q4 2025 | $22.6M | $-10.4M | $-0.25 |
| FY 2025 | $90.5M | $-54.0M | $-1.33 |
| Q3 2025 | $21.5M | $-14.0M | $-0.34 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$10.00
Target (Median)
$9.75
Target Range
$2.50 - $20.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
0.28
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.